MS: A common inflammatory-degenerative CNS disease
==================================================

Multiple sclerosis (MS) is the most common, non-traumatic cause of neurological disability among young adults in Western Europe and North America. The current hypothesis asserts that MS is triggered by environmental factors in individuals with complex genetic-risk profiles. As with other autoimmune diseases, MS shows moderate polygenic inheritability and may be caused or exacerbated by environmental exposure such as viral infections or vitamin D deficiency (Correale et al., [@B12]). It is characterized by clinical and genetic heterogeneity and with individuals with MHC class II complex genes being most susceptible (Ballerini et al., [@B5]; Gourraud et al., [@B17]). Out of the MHC locus a plethora of genes have been described as minor contributors to genetic risk, among which are those encoding for IL-2 receptors and IFN-γ (Blankenhorn et al., [@B8]).

MS is characterized by inflammation of the central nervous system (CNS) in which focal lymphocytic infiltrations lead to damage of myelin and axons associated with neurological dysfunction. Initially, the inflammatory response is transient and remyelination occurs, but this is not durable and over time widespread microglial activation ensues along with extensive and chronic neurodegeneration.

The observation that histamine may be implicated in MS dates back to the early 1980s when Tuomisto et al. ([@B54]) showed that patients with remitting or progressive disease have histamine levels about 60% higher than controls. Another clinical study, though, did not show elevated concentrations of histamine and its metabolite methylhistamine in MS patients when compared, in this case, with individuals affected by other neurological diseases (Rozniecki et al., [@B44]). More recently, gene-microarray analysis has shown that histamine H~1~ receptor (H~1~R) expression is upregulated in MS lesions (Lock et al., [@B26]), and epidemiological studies suggest a protective effect of brain penetrating H~1~R antagonists (Alonso et al., [@B1]). Furthermore, in a small pilot study, a cohort of MS patients treated with an H~1~R antagonist showed signs of neurological amelioration (Logothetis et al., [@B27]). The H~1~R has long been associated with inflammatory responses and for decades, the antiallergic and antiinflammatory activities of H~1~R antagonists have been used in therapy. Possible explanations of the therapeutic potential of H~1~R antagonists come from preclinical results in experimental allergic encephalomyelitis (EAE) in mice.

EAE is a good model for studying MS
===================================

Pathological features of MS are studied in three main animal models: toxic induction of disease, viral induction, and several types of EAE. Cuprizone and lysolecithine, for example, are used to investigate demyelination and remyelination in the CNS (reviewed in Woodruff and Franklin, [@B56]; Kipp et al., [@B23]), and to investigate how viral infections can induce CNS autoimmunity; Theiler\'s murine encephalomyelitis virus (TMEV) inoculated intracerebrally is a currently used experimental protocol (Olson et al., [@B36]). EAE may be actively induced by immunization of susceptible mouse strains with myelin proteins or myelin protein immunodominant peptides in the presence of complete Freund\'s adjuvant (CFA), or may be passively induced by transfer of myelin specific T cells. EAE, in most animal models, is mainly driven by MHC class II restricted, autoimmune CD4^+^ T cells and the clinical course depends on the immunization protocol, as not all combinations of genetic background, antigen, and adjuvant induce EAE. Classically, EAE immunized animals develop an ascending flaccid paralysis from tail to head with variable disease score; manifestation of clinical symptoms may be relapsing remitting, monophasic, or chronic. In active disease pathogenesis of EAE, two main steps are usually described: priming of myelin-reactive T cells and CNS invasion through the blood brain barrier (BBB). Once cells invade the CNS, local, and infiltrated antigen presenting cells (APCs) will present myelin peptides for full activation. Many different types of cells contribute to the development of the disease: APCs, mainly dendritic cells (DCs), B cells, microglia, macrophages, and astrocytes, although astrocytes have an unclear function in EAE development (Volterra and Meldolesi, [@B55]).

For many years the principal paradigm of EAE pathogenesis has been centered on IFN-γ producing T cells (Th1). These cells differentiate upon exposure to IL-12 and IFN-γ, are characterized by transcription factors T-bet, STAT1, STAT4 and are found as infiltrates in CNS lesions. With time this paradigm has been partially revised and a recently described T cell subpopulation has been shown to have a central role in disease pathology: Th17 cells that differentiate in the presence of IL-6 and TGF-β and need RORγt as a transcription factor (Gutcher and Becher, [@B19]). Th17 cells have been extensively studied in several autoimmune diseases and there is wide agreement on the instability of the phenotype that may switch between Th1 and Th17. This plasticity derives from epigenetic factors with Th17-derived Th1 cells promoting autoimmune diseases (Annunziato et al., [@B2]; Mukasa et al., [@B33]). Altogether, the studies on CD4^+^ T cells involved in EAE do not ascribe a particular role to one specific T cell population, and T helper cells may undergo alterations. Furthermore, recent observations suggest that EAE can elicit both Th1 and Th2 immune responses in the same subjects, i.e., elements of the Th2 cell-mediated allergic response are associated with autoimmune demyelination (Pedotti et al., [@B41]).

In conclusion, EAE has provided mechanistic insights into the complex pathogenesis of MS and has proven to be a good model for the preclinical testing of new diagnostic or treatment modalities. In addition, it is considered a well-suited model because of its histopathological and immunological similarities to MS (Schreiner et al., [@B48]). Consequently, the large majority of studies looking for a possible implication of histamine in autoimmune diseases have been performed using the murine EAE experimental model.

Histamine in autoimmune diseases
================================

Histamine has long been known to be a major promoter of allergic inflammatory conditions and gastric acid secretion. Synthesized by histidine decarboxylase (HDC) from histidine, histamine was later described as a neurotransmitter in the CNS that regulates several physiological processes and homeostatic functions including cognition, arousal, circadian, and feeding rhythms (Haas et al., [@B21]). These effects are mediated through four distinct G protein-coupled receptors (H~1~R, H~2~R, H~3~R, and H~4~R) with very low sequence homology. The H~1~R couples to G~*q*~ proteins, leading to phospholipase C activation and calcium mobilization (Bakker et al., [@B4]). The H~2~R activates Gα~*s*~ and increases camp formation, whereas the H~3~R mediates its function through Gα~*i*/*o*~, inhibits cAMP synthesis (Bakker et al., [@B4]), activates MAP kinases and the AKT/GSK3β axis (Bongers et al., [@B9]; Mariottini et al., [@B30]).

Inflammatory responses consequent to histamine release have long been thought to be mediated by the H~1~R, and antihistamines commonly used to treat allergies are H~1~R antagonists. The discovery of a fourth histamine receptor (H~4~R) and its expression on virtually all inflammatory and immune cells, though, has prompted a reassessment of the role of histamine in inflammatory and immune disorders and widened the spectrum of potential therapeutic interventions (Thurmond et al., [@B53]). The H~4~R is coupled to Gα~*i*/*o*~ proteins (Liu et al., [@B25]) and to the β-arrestin pathway (Rosethorne and Charlton, [@B43]), and signals via intracellular increases of calcium. Its functions include mediation of calcium mobilization, shape change, actin polymerization (Barnard et al., [@B6]) chemotaxis of mast cells, and eosinophils (Buckland et al., [@B10]), and up-regulation of adhesion molecules (Buckland et al., [@B10]).

All histamine receptors are expressed on the complement of cells involved in autoimmune diseases, with the exception of the H~3~R that is normally not expressed by hematopoietic cells, but is mostly confined to the CNS (Passani et al., [@B39]). Histamine participates in the development and progression of EAE as it controls accessibility to the site of inflammation by modulating vasopermeability and adhesion molecule expression, chemotaxis, and the cytokine profile of DCs and T lymphocytes, the main players in autoimmune diseases.

Role of histamine receptors in EAE: controversial results
=========================================================

The regulatory functions of histamine relevant to the onset and progression of neuroinflammatory diseases and in particular EAE, are being studied in genetically modified mice lacking histaminergic receptors, and with relatively selective agonists and antagonists. Hence, the contribution of each histamine receptor in autoimmune diseases has been identified. Histamine plays a complex role with varying and counteracting effects, depending on the receptor subtypes being activated and the targeted tissue (see Table [1](#T1){ref-type="table"}). *In vitro* experiments have shown that activation of H~1~R and H~2~R on DCs modulates cytokine and chemokine production and their ability to drive CD4^+^ T-cell differentiation to the Th2 phenotype. On the other hand, H~4~R activation modulates chemotaxis (reviewed in Schneider et al., [@B47]). Depending on the receptor engaged on polarized T cells, histamine can promote Th1 responses through H~1~R and down-regulate both Th1 and Th2 responses through H~2~R (Jutel et al., [@B22a]). Similarly to DCs, H~1~R and H~4~R activation on CD4^+^ T cells induces chemotaxis *in vitro*, whereas H~1~R and H~2~R modulate cytokine production (Schneider et al., [@B47]).

###### 

**Histamine receptors and EAE**.

  **Histamine receptor**   **EAE**         **Investigated cell types**               **Pharmacological target**   **Disease outcome**                                      **Reference**
  ------------------------ --------------- ----------------------------------------- ---------------------------- -------------------------------------------------------- -------------------------
  H~1~                     SJL mice        Increased H~1~R expression on Th1 cells   H~1~R antagonism             Less severe disease                                      Pedotti et al., [@B41]
                           PLP~139--151~                                                                                                                                   
                                           Humoral immunoresponses                                                                                                         El Behi et al., [@B15]
                           MOG~35--55~     CD4^+^T cells                                                          Reduced IFN-γ, increased IL-4                            Ma et al., [@B29]
                           H~1~R-KO mice                                                                                                                                   Noubade et al., [@B35]
                                                                                                                  Less severe disease                                      
                           MOG~35--55~     Endothelial cells                         H~1~R overexpression         Restored BBB integrity                                   Lu et al., [@B28]
                           H~1~R-KO mice                                                                          Less severe disease                                      
                           PLP~139--151~   CD3^+^T cells                             H~1~R activation             Reduced IFN-γ                                            Lapilla et al., [@B24]
                           SJL mice                                                                               Decreased endothelial adhesiveness                       
  H~2~                     MOG~35--55~     APC Th1                                                                Reduced cytokines                                        Teuscher et al., [@B51]
                           H~2~R-KO mice                                                                          Inhibition of cell polarization                          
                                                                                                                  Less severe disease                                      
                           MOG~35--55~     Proinflammatory cells                     H~2~R activation             Less severe disease                                      Emerson et al., [@B16]
                           C57/Bl6                                                                                                                                         
                           PLP~139--151~   CD3^+^T cells                             H~2~R activation             Reduced IFN-γ                                            Lapilla et al., [@B24]
                           SJL mice                                                                               Decreases endothelial adhesivness                        
  H~3~                     MOG~35--55~     Th1                                                                    Increased expression of chemokines/chemokine receptors   Teuscher et al., [@B52]
                           H~3~R-KO mice   Endothelial cells                                                                                                               
                                                                                                                  BBB deregulation                                         
                                                                                                                  More severe disease                                      
  H~4~                     MOG~35--55~     Treg                                                                   Lower frequency                                          del Rio et al., [@B13]
                           H~4~R-KO mice   Th17                                                                   Higher frequency                                         
                                                                                                                  More severe disease                                      
                           MOG~35--55~     Th1                                       H~4~ R antagonism            Increased IFN-γ, reduced IL-10                           Passani et al., [@B38]
                           C57/Bl6 mice    Mdc                                                                                                                             
                                                                                                                  More severe disease                                      
                           MOG~35--55~     CD3^+^T cells                                                          Increased IFN-γ, TNF, More severe disease                Musio et al., [@B34]
                           HDC KO mice                                                                                                                                     

APC, antigen presenting cells; BBB, blood brain barrier; mDC, myeloid dendritic cells; MOG~35--55~, Myelin Oligodendrocyte Glycoprotein; PLP~139--151~, Myelin Proteolipid Protein.

Mast cells are generally thought to be the major sources of histamine and can themselves be modulated by histamine as they express H~1~R, H~2~R, and H~4~R. There is ample correlative and direct evidence that supports mast cell involvement in amplifying the severity of both MS and EAE. Mast cell-deficient W/W(v) mice exhibit significantly less severe disease than wild type littermates in both progressive (Sayed et al., [@B45]) and relapsing-remitting (Secor et al., [@B49]) models of EAE.

Susceptibility to EAE requires expression of *Hrh1*, the gene encoding the H~1~R (Ma et al., [@B29]). The H~1~R is expressed on Th1 cells in EAE mice brain lesions (Pedotti et al., [@B41]), where its presence is necessary for full encephalitogenic expression (Noubade et al., [@B35]). Furthermore, expression of the H~1~R is up-regulated on encephalitogenic PLP~139--151~ specific Th1 compared to Th2 cell lines (Pedotti et al., [@B41]). Not surprisingly, specific pharmacological targeting of H~1~R results in amelioration of EAE (Pedotti et al., [@B41]; El Behi et al., [@B15]) and H~1~R-deficient (H~1~R-KO) mice exhibit a significant delay in the onset of EAE and a reduction in the severity of the clinical signs compared with WT mice (Ma et al., [@B29]; Table [1](#T1){ref-type="table"}). In fact, CD4^+^ T-cells from H~1~R-KO mice produce significantly less IFN-γ and more IL-4 (that induces differentiation of naive CD4^+^ T cells to Th2 cells) in *in vitro* assays compared to wild-type controls, indicating that H~1~R signaling in CD4^+^ T cells plays a central role in regulating pathogenic T-cell responses (Ma et al., [@B29]).

The H~2~R also seems to partially regulate encephalitogenic Th1-cell responses and EAE susceptibility, as H~2~R-KO mice develop a less severe disease than wild-type littermates during the acute, early phase (Teuscher et al., [@B51]). The failure of H~2~R-KO mice to generate encephalitogenic Th1 effector cell responses is attributed to H~2~R-mediated regulation of cytokine production by DCs that affects T-cell-polarizing activity. In conclusion, H~1~R and H~2~R seem to have a pro-inflammatory role and disease-promoting effect, but the story is not quite as simple as that, as H~1~R or H~2~R activation may also play an important role in limiting autoimmune responses.

Adhesion of T cells to the inflamed microcirculation precedes their penetration in the brain parenchyma, following breakdown of BBB integrity. H~1~Rs are expressed on endothelial cells where they increase vascular permeability (Owen et al., [@B37]); however, functional expression of the H~1~R on endothelial cells does not restore EAE susceptibility in H~1~R-KO mice, rather, overexpression of the H~1~R further suppresses the residual symptoms shown by H~1~R-KO mice, suggesting that endothelial H~1~R signaling is needed to maintain cerebrovascular integrity (Lu et al., [@B28]). Pedotti and colleagues (Lapilla et al., [@B24]) have demonstrated that histamine activating H~1~R and H~2~R, inhibits *in vitro* the proliferation of mouse CD3^+^ T cells reactive against PLP~139--151~, and their adhesiveness to the inflamed endothelium. Also, treatment with an H~2~R agonist reduces the clinical signs of murine EAE (Emerson et al., [@B16]; Table [1](#T1){ref-type="table"}). As pointed out by the authors (Pedotti et al., [@B41]; Lapilla et al., [@B24]) methodological differences may account for the discrepancies observed in *in vivo* and *ex vivo* experiments, such as the immunization protocols adopted. Also, *ex vivo* experiments may not necessarily recapitulate the integrated action of signals relevant to EAE and components of an integrated system maybe lost. On the other hand, genetically modified mice may carry alterations of systems other than the targeted ones, and activation of vicarious mechanisms may hinder the effects related to the deleted gene(s). In fact, the complete lack of HDC and histamine synthesis in HDC-KO mice exacerbates EAE and increases the production of proinflammatory cytokines (Musio et al., [@B34]). This phenotype does not seem to summarize the lack of signaling at histamine receptors observed in H~1~R- and H~2~R-deficient mice, rather a reduced effect of histamine at H~3~R and H~4~R (see below).

As mentioned earlier, H~3~R are normally not expressed by hematopoietic cells, but are mostly confined to the CNS where they limit histamine synthesis and release (Arrang et al., [@B3]), as well as regulate other neurotransmitters\' release (reviewed in Passani and Blandina, [@B40]). It was recently shown that deletion of the H~3~R leads to more severe EAE, an effect associated with altered BBB permeability and an unexpected increased expression of chemokines/chemokine receptors that promote entry into the CNS on peripheral T cells that do not themselves express H~3~R (Teuscher et al., [@B52]). The authors suggest that neuronal H~3~R may serve as a central control of cerebrovascular tone, and negatively regulate susceptibility to neuroinflammatory diseases. Their proposed mechanism states that in H~3~R-KO mice the absence of a presynaptic inhibition would lead to increased release of neurotransmitters and postsynaptic activity that would exert neurogenic control of BBB permeability and T cell chemokine profile.

The complex role of H~4~R during inflammatory responses in EAE
==============================================================

The distribution of the H~4~R on immune cells and its primary role in inflammatory functions has made it a very attractive target for the treatment of asthma and autoimmune diseases (Bhatt et al., [@B7]). Recent evidence has also shown the topological and functional localization of the H~4~R in the CNS of both humans and rodents (Connelly et al., [@B11]; Strakhova et al., [@B50]). Immunohistochemical detection revealed that H~4~Rs are expressed on the soma of sensory neurons with intense staining of small and medium diameter neurons, as well as lamina I-II of the lumbar spinal cord, where the immunoreactivity pattern suggests localization with terminals of primary afferent neurons (Connelly et al., [@B11]). These findings widen the range of therapeutic potentials of compounds targeting the H~4~R, as antagonists might relieve itching by decreasing not only inflammation, but also the urge to scratch. The H~4~R is detected on hematopoietic progenitor cells (Petit-Bertron et al., [@B42]), and its activation before exposure to growth factors leads to a drastic decrease in the percentage of cycling cells (Schneider et al., [@B46]). The H~4~R expression is dynamic as it is up-regulated during the differentiation from human monocytes to DCs (Gutzmer et al., [@B20]). In addition, receptor levels may change with the progression of pathophysiological responses, e.g., inflammatory stimuli can up-regulate the expression of H~4~R in monocytes (Dijkstra et al., [@B14]). The anti-inflammatory effect of H~4~R antagonists in asthma and pruritus is consolidated (reviewed in Thurmond et al., [@B53]; Zampeli and Tiligada, [@B57]). The use of selective antagonists demonstrated a pro-inflammatory role for this receptor in several paradigms and suggested a facilitating action on autoimmune diseases (Jadidi-Niaragh and Mirshafiey, [@B22]). Furthermore H~4~R are expressed on Th17 cells where their activation increases IL-17 production (Mommert et al., [@B31]). Quite surprisingly though, mice with a disrupted H~4~R gene develop more severe EAE together with increased neuroinflammatory signs and increased BBB permeability compared to wild type mice (del Rio et al., [@B13]). In this paradigm, H~4~R-KO mice have a lower frequency of infiltrating Treg cells that possess disease suppressive activity, more precisely during CNS invasion at day 10 post immunization (10 dpi), and a higher proportion of inflammatory Th17. Preliminary data in our laboratory are corroborating these findings (Table [1](#T1){ref-type="table"}), as H~4~R antagonists such as JNJ7777120 administered daily for eight days to EAE mice at the onset of clinical signs exacerbate the clinical and neuropathological signs of the disease (Passani et al., [@B38]). In our model, a decreased release of regulatory cytokines such as IL-10 is accompanied with augmented production of IFN-γ in MOG~35--55~-specific T cells during the acute phase of the disease (18--20 dpi), suggesting a more complex role of H~4~R not only on regulatory mechanisms of the immune response but also on T effector cells.

In conclusion, the use of different inflammatory and immune models is producing conflicting results about the role of the H~4~R in allergic and immune responses. For example, recent data show that the activation, and not antagonism, of H~4~R leads to reduced pro-inflammatory capacity of a subpopulation of DCs found in inflamed tissues in atopic dermatitis (Gschwandtner et al., [@B18]). Also, in a murine model of allergic asthma, the administration of H~4~R agonists mitigated airway hyperreactivity and inflammation with a suggested direct effect on T regulatory cell recruitment (Morgan et al., [@B32]). It is clear that in the context of the conflicting activities of the H~4~R that depend on its activation on different hematopoietic cells, additional research is needed to clarify whether H~4~R agonists can yield promising drugs in the treatment of autoimmune diseases.

Conclusions {#s1}
===========

Histamine receptors play multiple roles in immune reactions and autoimmune disorders. Strategies aimed at interfering with the histamine axis may have relevance in the therapy of autoimmune diseases of the CNS as histamine may determine, through different receptor activation pathways, a shift in T helper cell subpopulation, may influence migration of lymphocytes and myeloid cells during CNS invasion, interfere with antigen presentation at the immune synapse level and finally, determine variations in normal neuronal functions. It will be of paramount importance to define the temporal sequence of histamine receptor activation during disease initiation in peripheral tissues and during CNS invasion. Hopefully, this will help the scientific community to put the sometimes confusing and contradictory observations reviewed here into better focus and provide a perspective for evaluating potential therapeutic interventions using histaminergic compounds.
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